HK1071066A1 - Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment - Google Patents

Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment

Info

Publication number
HK1071066A1
HK1071066A1 HK05103834.9A HK05103834A HK1071066A1 HK 1071066 A1 HK1071066 A1 HK 1071066A1 HK 05103834 A HK05103834 A HK 05103834A HK 1071066 A1 HK1071066 A1 HK 1071066A1
Authority
HK
Hong Kong
Prior art keywords
bcl
gossypol
docetaxel
paclitaxel
cancer treatment
Prior art date
Application number
HK05103834.9A
Other languages
English (en)
Inventor
Shaomeng Wang
Dajun Yang
Original Assignee
Univ Michigan
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Univ Georgetown filed Critical Univ Michigan
Publication of HK1071066A1 publication Critical patent/HK1071066A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK05103834.9A 2001-05-30 2005-05-06 Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment HK1071066A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29398301P 2001-05-30 2001-05-30
PCT/US2002/017206 WO2002097053A2 (en) 2001-05-30 2002-05-30 Small molecule antagonists of bcl2 family proteins

Publications (1)

Publication Number Publication Date
HK1071066A1 true HK1071066A1 (en) 2005-07-08

Family

ID=31495521

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05103834.9A HK1071066A1 (en) 2001-05-30 2005-05-06 Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment

Country Status (18)

Country Link
US (1) US20030008924A1 (xx)
EP (1) EP1474121B1 (xx)
JP (1) JP2005515158A (xx)
KR (1) KR20040108528A (xx)
CN (1) CN1589135A (xx)
AT (1) ATE474568T1 (xx)
AU (1) AU2002305769B2 (xx)
CA (1) CA2449245A1 (xx)
DE (1) DE60237115D1 (xx)
ES (1) ES2349349T3 (xx)
HK (1) HK1071066A1 (xx)
IL (1) IL159110A0 (xx)
MX (1) MXPA03010977A (xx)
NO (1) NO20035301D0 (xx)
NZ (1) NZ529792A (xx)
SG (1) SG157952A1 (xx)
WO (1) WO2002097053A2 (xx)
ZA (1) ZA200309306B (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20023357D0 (no) * 2002-04-19 2002-07-11 Amersham Health As Blanding
US20070060615A1 (en) * 2003-02-18 2007-03-15 University Of South Florida Method of Modulating Apoptosis Through Modulation of E2F1
SI1653943T1 (sl) * 2003-06-25 2008-08-31 Burnham Inst Derivati katehola za zdravljenje raka
US7342046B2 (en) * 2004-03-25 2008-03-11 The Regents Of The University Of Michigan Gossypol co-crystals and the use thereof
BRPI0511070A (pt) 2004-06-17 2007-11-27 Infinity Pharmaceuticals Inc compostos e processos para inibição da interação de proteìnas bcl com parceiros de ligação
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
US20060247305A1 (en) * 2005-03-11 2006-11-02 Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
WO2007126840A2 (en) * 2006-03-30 2007-11-08 The Regents Of The University Of Michigan Production of gossypol co-crystals
US20100137239A1 (en) 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US7857804B2 (en) 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
US20090030088A1 (en) * 2007-04-20 2009-01-29 Clemson University Therapeutic benefits of gossypol, 6-methoxy gossypol, and 6,6'-dimothxy gossypol
WO2009036035A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
WO2009052443A1 (en) * 2007-10-19 2009-04-23 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
EP2323648A4 (en) * 2008-08-14 2012-10-03 Uab Research Foundation ANTI-ARTHRITIS AGENTS, METHODS FOR THEIR USE, METHODS FOR THEIR IDENTIFICATION AND RELEVANT KITS
BRPI0922823A2 (pt) * 2008-12-11 2015-08-18 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
EA201270347A1 (ru) * 2009-10-08 2012-11-30 Санфорд-Бернхам Медикал Ресерч Инститъют Производные апогоссиполона в качестве противоопухолевых агентов
SG10201505475XA (en) 2010-07-12 2015-09-29 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
WO2012151544A1 (en) * 2011-05-05 2012-11-08 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US8940737B2 (en) * 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
BR112014015308A8 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com contrapartes de ligação
BR112014015442A8 (pt) 2011-12-23 2017-07-04 Novartis Ag compostos e composições para inibir a interação de bcl2 com parceiros de ligação
EA201491260A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
JP2015503515A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物および組成物
WO2013096059A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
WO2015123618A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for increasing bcl2 gene expression
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
WO2016014625A1 (en) 2014-07-22 2016-01-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells
CN105884634B (zh) * 2015-01-05 2019-06-04 南开大学 棉酚衍生物和它们的制备,在农药上的应用及抗癌活性
US10975051B2 (en) 2015-08-12 2021-04-13 Memorial Sloan Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
WO2017087810A1 (en) * 2015-11-20 2017-05-26 Memorial Sloan-Kettering Cancer Center Method for screening inhibitors targeting anti-apoptotic survival pathways
CN108697667A (zh) 2016-02-18 2018-10-23 延世大学校产学协力团 用于治疗癌症、含有多酚化合物作为活性成分的药物组合物
WO2017142348A1 (ko) * 2016-02-18 2017-08-24 연세대학교 산학협력단 폴리페놀 화합물을 유효성분으로 포함하는 암 치료용 약학조성물
US10807977B2 (en) 2016-04-21 2020-10-20 Bioventures, Llc Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
CN109718377B (zh) * 2017-10-31 2021-03-26 中国科学院脑科学与智能技术卓越创新中心 KPNB1抑制剂和Bcl-xL抑制剂在制备抗肿瘤药物中的应用
JP7385284B2 (ja) 2018-01-22 2023-11-22 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー 癌処置のためのｂｃｌ－２タンパク質分解剤
CN109876145A (zh) * 2019-04-25 2019-06-14 中国科学院化学研究所 醋酸棉酚和化疗药的联合用药物
MX2021015317A (es) 2019-06-12 2022-03-11 Juno Therapeutics Inc Terapia de combinacion de una terapia citotoxica mediada por celulas y un inhibidor de una proteina de la familia bcl2 de prosupervivencia.
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
AU2022405016A1 (en) 2021-12-09 2024-06-06 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806568A (en) * 1985-09-12 1989-02-21 Research Corporation Gossypol derivatives
US5026726A (en) * 1989-12-11 1991-06-25 The University Of New Mexico Gossylic iminolactones and gossylic lactones and their anti-viral activities
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
AU2002305769B2 (en) 2007-07-19
ZA200309306B (xx) 2006-07-26
EP1474121A2 (en) 2004-11-10
WO2002097053A3 (en) 2004-09-10
ATE474568T1 (de) 2010-08-15
NO20035301D0 (no) 2003-11-28
EP1474121B1 (en) 2010-07-21
SG157952A1 (en) 2010-01-29
DE60237115D1 (de) 2010-09-02
WO2002097053A2 (en) 2002-12-05
CA2449245A1 (en) 2002-12-05
NZ529792A (en) 2007-04-27
MXPA03010977A (es) 2005-04-08
US20030008924A1 (en) 2003-01-09
IL159110A0 (en) 2004-06-01
JP2005515158A (ja) 2005-05-26
ES2349349T3 (es) 2010-12-30
CN1589135A (zh) 2005-03-02
EP1474121A4 (en) 2006-05-03
KR20040108528A (ko) 2004-12-24

Similar Documents

Publication Publication Date Title
HK1071066A1 (en) Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment
BR0201714A (pt) Uso de hidroxiflavanonas para encobrir o sabor amargo
EP2476461A3 (en) Formulations For Cancer Treatment
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
HK1109638A1 (en) Dr5 antibodies and uses thereof dr5
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
EP2497478A3 (en) Oligosaccaride compositions and use thereof in the treatment of infection
EP1181013A4 (en) METHOD AND COMPOSITION FOR TREATING CANCER
IL169897A0 (en) Sustituted heterocycles
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
MY143795A (en) Tetrahydropyridoindole derivatives
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
NO20085147L (no) Sammensetning for behandling av motstandsdyktige kreftformer omfattende oridonin
MX2007012623A (es) Inulina de cadena larga.
TW200716088A (en) Formulations and methods for treating amyloidosis
HK1083296A1 (en) Enteral composition for the prevention and/or treatment of sepsis
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
EP1773363A4 (en) NGNA COMPOSITIONS AND METHODS OF USE THEREOF
SI1951738T1 (sl) Nadaljnje kristalinične oblike rostafuroksina
PL1677818T3 (pl) Stabilne kompozycje wodne zawierające G-CSF
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
GB2430365B (en) High-purity texaphyrin metal complexes
WO2008080682A3 (de) Synergistische kombination von seidenproteinen und ausgewählten metallen

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220529